Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

New cytokine-targeted therapies show promise for treating alopecia areata.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

JAK inhibitors are effective treatments for alopecia areata.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Immunoadsorption successfully treated a man's resistant polymyositis.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Mesalazine showed limited effectiveness in treating children with severe alopecia areata.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.